Yet another presentation this week from Antaros Medical. This time, Nicolas Geades, Imaging Director, will present the role of imaging in obesity and metabolic disease drug development at the Obesity Drug Development Summit Europe in Barcelona.
Obesity and metabolic diseases are multifactorial conditions with complex pathophysiology. As drug development in this space accelerates, there is a growing need for tools that can provide deeper insights into treatment effects beyond traditional endpoints like weight loss. Weight loss alone provides limited insight into treatment efficacy and body composition changes. Imaging can help differentiate therapies by revealing the source of weight loss—such as changes in lean tissue or fat redistribution— as well as capturing effects on other metabolically linked organs including the liver, kidney and heart. These insights are essential for understanding mechanisms of action and demonstrating broader therapeutic benefits in an increasingly competitive market.
Join Nicolas to hear more about this exciting topic. More specifically he will cover:
- Imaging methodologies (e.g. DXA, MRI, CT) provide information about different aspects of body composition meeting different needs in clinical trials
- Body composition assessment of muscle and adipose tissue can be combined with measures of other end-organ effects for a deeper understanding of treatment responses
- Imaging can be a very powerful tool, even in early PK or PD studies
Nicolas will present on October 1st @ 14.40 at the Obesity Drug Development Summit Europe. The Summit takes place on 1-2 October in Barcelona.